Thomas F Delaney

List of Publications by Year
in descending order

122 papers	5,907 citations	76326 40 h-index	76900 74 g-index
123 all docs	123 docs citations	123 times ranked	6410 citing authors

#	Article	IF	Citations
1	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. JAMA Oncology, 2018, 4, 963.	7.1	426
2	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 2016, 34, 460-468.	1.6	363
3	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. JAMA Oncology, 2019, 5, 1020.	7.1	353
4	Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. International Journal of Radiation Oncology Biology Physics, 2003, 56, 1117-1127.	0.8	289
5	Phase II Study of High-Dose Photon/Proton Radiotherapy in the Management of Spine Sarcomas. International Journal of Radiation Oncology Biology Physics, 2009, 74, 732-739.	0.8	247
6	Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1514-1521.	0.8	217
7	Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. Journal of Surgical Oncology, 2014, 110, 115-122.	1.7	184
8	Radiation Therapy for Control of Soft-Tissue Sarcomas Resected With Positive Margins. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1460-1469.	0.8	161
9	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. Journal of Clinical Oncology, 2020, 38, 1569-1579.	1.6	158
10	Protonâ€based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer, 2011, 117, 4522-4530.	4.1	149
11	High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors. Journal of Neurosurgery: Spine, 2015, 23, 788-797.	1.7	133
12	A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1596-1606.	0.8	113
13	Prognostic Factors and Outcomes of Patients with Myxofibrosarcoma. Annals of Surgical Oncology, 2013, 20, 80-86.	1.5	105
14	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Annals of Surgical Oncology, 2021, 28, 7873-7888.	1.5	105
15	Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel. International Journal of Radiation Oncology Biology Physics, 2015, 92, 602-612.	0.8	102
16	Clinicopathologic characteristics of poorly differentiated chordoma. Modern Pathology, 2018, 31, 1237-1245.	5.5	102
17	Proton Radiotherapy for Pediatric Ewing's Sarcoma: Initial Clinical Outcomes. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1142-1148.	0.8	100
18	Definitive High-Dose Photon/Proton Radiotherapy for Unresected Mobile Spine and Sacral Chordomas. Spine, 2013, 38, E930-E936.	2.0	99

#	Article	IF	Citations
19	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. International Journal of Radiation Oncology Biology Physics, 2019, 105, 64-72.	0.8	99
20	Proton-Beam, Intensity-Modulated, and/or Intraoperative Electron Radiation Therapy Combined with Aggressive Anterior Surgical Resection for Retroperitoneal Sarcomas. Annals of Surgical Oncology, 2010, 17, 1515-1529.	1.5	97
21	Gastrointestinal Stromal Tumors, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 853-862.	4.9	96
22	Advanced-Technology Radiation Therapy in the Management of Bone and Soft Tissue Sarcomas. Cancer Control, 2005, 12, 27-35.	1.8	94
23	Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiotherapy and Oncology, 2014, 113, 89-94.	0.6	93
24	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. Journal of the National Cancer Institute, 2017, 109, .	6.3	82
25	Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. Radiotherapy and Oncology, 2016, 119, 14-21.	0.6	72
26	Updated Outcome and Analysis of Tumor Response in Mobile Spine and Sacral Chordoma Treated With Definitive High-Dose Photon/Proton Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 254-262.	0.8	69
27	Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis Type 1. Journal of Neurosurgery, 2013, 118, 142-148.	1.6	65
28	Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2021, 11, 339-351.	2.1	65
29	Comparison of Perioperative Radiation Therapy and Surgery Versus Surgery Alone in 204 Patients With Primary Retroperitoneal Sarcoma. Annals of Surgery, 2015, 262, 156-162.	4.2	64
30	Combination Short-Course Preoperative Irradiation, Surgical Resection, and Reduced-Field High-Dose Postoperative Irradiation in the Treatment of Tumors Involving the Bone. International Journal of Radiation Oncology Biology Physics, 2009, 73, 259-266.	0.8	62
31	Long-Term Outcomes After Proton Beam Therapy for Sinonasal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 95, 368-376.	0.8	60
32	Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Advances in Radiation Oncology, 2017, 2, 85-93.	1.2	57
33	The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma. European Journal of Cancer, 2020, 125, 130-141.	2.8	57
34	Proton Therapy in the Clinic. Frontiers of Radiation Therapy and Oncology, 2011, 43, 465-485.	1.4	55
35	Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiotherapy and Oncology, 2019, 137, 61-70.	0.6	54
36	Characteristics and Patterns of Metastatic Disease from Chordoma. Sarcoma, 2015, 2015, 1-7.	1.3	53

#	Article	IF	Citations
37	How Does the Level of Sacral Resection for Primary Malignant Bone Tumors Affect Physical and Mental Health, Pain, Mobility, Incontinence, and Sexual Function?. Clinical Orthopaedics and Related Research, 2016, 474, 687-696.	1.5	51
38	Prognostic factors in alveolar soft part sarcoma: A SEER analysis. Journal of Surgical Oncology, 2016, 113, 581-586.	1.7	50
39	Sacral Insufficiency Fractures are Common After High-dose Radiation for Sacral Chordomas Treated With or Without Surgery. Clinical Orthopaedics and Related Research, 2016, 474, 766-772.	1.5	43
40	A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Practical Radiation Oncology, 2014, 4, 316-322.	2.1	42
41	HIF-1 Alpha Regulates the Response of Primary Sarcomas to Radiation Therapy through a Cell Autonomous Mechanism. Radiation Research, 2015, 183, 594.	1.5	41
42	The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated With Radiotherapy. Oncologist, 2016, 21, 1269-1276.	3.7	41
43	Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution. Spine Journal, 2019, 19, 869-879.	1.3	41
44	Chordomas and chondrosarcomas-The role of radiation therapy. Journal of Surgical Oncology, 2016, 114, 564-569.	1.7	39
45	Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1226-1233.	0.8	39
46	Low dose radiotherapy is associated with local complications but not disease control in sacral chordoma. Journal of Surgical Oncology, 2019, 119, 856-863.	1.7	37
47	Myxoid Liposarcoma: Treatment Outcomes from Chemotherapy and Radiation Therapy. Sarcoma, 2018, 2018, 1-6.	1.3	33
48	Overall survival advantage of chemotherapy and radiotherapy in the perioperative management of large extremity and trunk soft tissue sarcoma; a large database analysis. Radiotherapy and Oncology, 2017, 124, 277-284.	0.6	31
49	Real-Time Rationing of Scarce Resources: The Northeast Proton Therapy Center Experience. Journal of Clinical Oncology, 2004, 22, 2246-2250.	1.6	29
50	Evaluating Intensity Modulated Proton Therapy Relative to Passive Scattering Proton Therapy for Increased Vertebral Column Sparing in Craniospinal Irradiation in Growing Pediatric Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 37-46.	0.8	29
51	Retroperitoneal Sarcoma Target Volume and Organ at Risk Contour Delineation Agreement Among NRG Sarcoma Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1053-1059.	0.8	28
52	Innovative radiotherapy of sarcoma: Proton beam radiation. European Journal of Cancer, 2016, 62, 112-123.	2.8	28
53	Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma. Journal of Surgical Oncology, 2016, 114, 814-820.	1.7	27
54	Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, 8500-8500.	1.6	26

#	Article	IF	Citations
55	Radiation therapy in retroperitoneal sarcoma management. Journal of Surgical Oncology, 2018, 117, 93-98.	1.7	25
56	Clinical Proton Radiation Therapy Research at the Francis H. Burr Proton Therapy Center. Technology in Cancer Research and Treatment, 2007, 6, 61-66.	1.9	24
57	Multiâ€institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. Journal of Surgical Oncology, 2020, 122, 877-883.	1.7	24
58	Radiation Therapy: Neoadjuvant, Adjuvant, or Not at All. Surgical Oncology Clinics of North America, 2012, 21, 215-241.	1.5	23
59	Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution. Sarcoma, 2019, 2019, 1-10.	1.3	23
60	Optimizing radiation therapy and post-treatment function in the management of extremity soft tissue sarcoma. Current Treatment Options in Oncology, 2004, 5, 463-476.	3.0	21
61	Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. International Journal of Radiation Oncology Biology Physics, 2019, 105, 90-95.	0.8	20
62	Radiation Strategies for Spine Chordoma. Neurosurgery Clinics of North America, 2020, 31, 263-288.	1.7	20
63	Analysis of setup uncertainties for extremity sarcoma patients using surface imaging. Practical Radiation Oncology, 2014, 4, 261-266.	2.1	19
64	Retroperitoneal Sarcoma (RPS) High Risk Gross Tumor Volume Boost (HR GTV Boost) Contour Delineation Agreement Among NRG Sarcoma Radiation and Surgical Oncologists. Annals of Surgical Oncology, 2015, 22, 2846-2852.	1.5	19
65	Acute gastrointestinal toxicity and bowel bag dose-volume parameters for preoperative radiation therapy for retroperitoneal sarcoma. Practical Radiation Oncology, 2016, 6, 360-366.	2.1	19
66	Margin reduction from image guided radiation therapy for soft tissue sarcoma: Secondary analysis of Radiation Therapy Oncology Group 0630 results. Practical Radiation Oncology, 2016, 6, e135-e140.	2.1	18
67	Malignant Soft-Tissue Sarcomas. Hematology/Oncology Clinics of North America, 2020, 34, 161-175.	2.2	18
68	Low-Dose Neoadjuvant External Beam Radiation Therapy for Soft Tissue Sarcoma. International Journal of Radiation Oncology Biology Physics, 2011, 80, 779-786.	0.8	17
69	[18F]-Fluoromisonidazole Positron Emission Tomography/Computed Tomography Visualization of Tumor Hypoxia in Patients With Chordoma of the Mobile and Sacrococcygeal Spine. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1030-1036.	0.8	16
70	Targeted next-generation sequencing of dedifferentiated chondrosarcoma in the skull base reveals combined TP53 and PTEN mutations with increased proliferation index, an implication for pathogenesis. Oncotarget, 2016, 7, 43557-43569.	1.8	16
71	Surgical placement of biologic mesh spacers prior to external beam radiation for retroperitoneal and pelvic tumors. Practical Radiation Oncology, 2013, 3, 199-208.	2.1	15
72	Post-operative renal function following nephrectomy as part of en bloc resection of retroperitoneal sarcoma (RPS). Journal of Surgical Oncology, 2015, 112, 98-102.	1.7	15

#	Article	IF	Citations
73	Improved local control with an aggressive strategy of preoperative (with or without intraoperative) radiation therapy combined with radical surgical resection for retroperitoneal sarcoma. Journal of Surgical Oncology, 2017, 115, 746-751.	1.7	14
74	Extraskeletal osteosarcoma: A large series treated at a single institution. Rare Tumors, 2018, 10, 203636131774965.	0.6	13
75	A Phase 1 Study of Nilotinib Plus Radiation in High-Risk Chordoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1496-1504.	0.8	13
76	Preoperative radiotherapy for retroperitoneal sarcoma. Lancet Oncology, The, 2021, 22, e1.	10.7	13
77	TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 386-386.	1.6	13
78	Clinical outcomes for patients after surgery and radiation therapy for mesenchymal chondrosarcomas. Journal of Surgical Oncology, 2016, 114, 982-986.	1.7	11
79	Thoracolumbar spinal cord tolerance to high dose conformal protonâ€“photon radiation therapy. Radiotherapy and Oncology, 2016, 119, 35-39.	0.6	9
80	Temporizing Wound VAC Dressing Until Final Negative Margins are Achieved Reduces Myxofibrosarcoma Local Recurrence. Annals of Surgical Oncology, 2021, 28, 9171-9176.	1.5	9
81	Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. Journal of Clinical Oncology, 2018, 36, 4116-4116.	1.6	9
82	Assessing the Safety and Utility of Wound VAC Temporization of the Sarcoma or Benign Aggressive Tumor Bed Until Final Margins Are Achieved. Annals of Surgical Oncology, 2022, 29, 2290-2298.	1.5	9
83	Charged Issues: Particle Radiation Therapy. Seminars in Radiation Oncology, 2018, 28, 75-78.	2.2	7
84	High-Dose Proton Beamâ€“Based Radiation Therapy in the Management of Extracranial Chondrosarcomas. International Journal of Particle Therapy, 2016, 3, 373-381.	1.8	7
85	Fine Tuning the Radiation Treatment for Extremity Soft Tissue Sarcomas. Annals of Surgical Oncology, 2018, 25, 3785-3786.	1.5	6
86	Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation. Sarcoma, 2018, 2018, 1-10.	1.3	6
87	Physical Function and Quality of Life After Resection of Mobile Spine Chondrosarcoma. Global Spine Journal, 2019, 9, 743-753.	2.3	6
88	Assessing second cancer risk after primary cancer treatment with photon or proton radiotherapy. Cancer, 2020, 126, 3397-3399.	4.1	6
89	AÂproofÂofÂconceptÂtreatment planningÂstudyÂofÂgated proton radiotherapy for cardiac soft tissue sarcoma. Physics and Imaging in Radiation Oncology, 2021, 19, 78-84.	2.9	6
90	Preliminary results of phase 2 trial of preoperative image guided intensity modulated proton radiation therapy (IMPT) with simultaneously integrated boost (SIB) to the high-risk margin for retroperitoneal sarcomas (RPS).. Journal of Clinical Oncology, 2021, 39, 11550-11550.	1.6	5

#	Article	IF	Citations
91	Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).. Journal of Clinical Oncology, 2017, 35, 4118-4118.	1.6	5
92	Comparison of 3D Conformal Proton Therapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Photon Therapy for Retroperitoneal Sarcoma. Sarcoma, 2022, 2022, 1-9.	1.3	4
93	The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. Advances in Radiation Oncology, 2021, 6, 100635.	1.2	3
94	Role of Radiation Therapy for Newly Diagnosed Retroperitoneal Sarcoma. Current Treatment Options in Oncology, 2021, 22, 75.	3.0	3
95	Osteosarcoma prognostic nomograms for predicting the 10-year probability of mortality and recurrence.. Journal of Clinical Oncology, 2017, 35, 11020-11020.	1.6	3
96	Bone Sarcomas and Desmoids. Hematology/Oncology Clinics of North America, 2020, 34, 177-188.	2.2	2
97	What Is the Role of Neoadjuvant Radiation Therapy for Retroperitoneal Sarcoma?. Advances in Surgery, 2020, 54, 273-284.	1.3	2
98	Lowâ€dose preoperative radiation, resection, and reducedâ€field postoperative radiation for soft tissue sarcomas. Journal of Surgical Oncology, 2021, 124, 400-410.	1.7	2
99	Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2015, 33, 4020-4020.	1.6	2
100	Nodal involvement and survival in synovial, clear cell, angio, rhabdo, and epithelioid sarcoma.. Journal of Clinical Oncology, 2018, 36, 11567-11567.	1.6	2
101	A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, 376-376.	1.6	2
102	Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. Journal of Clinical Oncology, 2019, 37, 392-392.	1.6	2
103	Novel Body Composition Predictors of Outcome in Patients With Angiosarcoma of the Breast: A Preliminary Study. Journal of Computer Assisted Tomography, 2020, 44, 605-609.	0.9	1
104	Circulating biomarkers in a phase II study of hypofractionated proton beam therapy (H-PBT) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2016, 34, 4083-4083.	1.6	1
105	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 4113-4113.	1.6	1
106	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 368-368.	1.6	1
107	Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.. Journal of Clinical Oncology, 2012, 30, 4021-4021.	1.6	1
108	Conditional survival of patients with nonmetastatic bone osteosarcoma.. Journal of Clinical Oncology, 2020, 38, e23511-e23511.	1.6	1

#	Article	IF	Citations
109	Utilization pattern and survival outcomes of adjuvant therapies in highâ€grade nonretroperitoneal abdominal soft tissue sarcoma: A populationâ€based study. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 101-113.	1.1	0
110	VAC temporization pending final margins after suprafascial myxofibrosarcoma excision to reduce the rate of local recurrence.. Journal of Clinical Oncology, 2021, 39, 11573-11573.	1.6	0
111	Outcomes of VAC temporization following the excision of microinvasive sarcomas pending negative formal pathologic margins.. Journal of Clinical Oncology, 2021, 39, e23559-e23559.	1.6	0
112	ASO Visual Abstract: Temporizing Wound VAC Dressing Until Final Negative Margins are Achieved Reduces Myxofibrosarcoma Local Recurrence. Annals of Surgical Oncology, 2021, 28, 475.	1.5	0
113	Careful with the Cauda. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1265.	0.8	0
114	Pseudoprogression of Malignant Peripheral Nerve Sheath Tumor in Patient with Neurofibromatosis Type 1, a Case Report. Case Reports in Oncology, 2021, 14, 1342-1346.	0.7	0
115	Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year follow-up study.. Journal of Clinical Oncology, 2012, 30, 10058-10058.	1.6	0
116	Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2013, 31, 4047-4047.	1.6	0
117	Association of perioperative radiation therapy with outcome in 204 patients with primary retroperitoneal sarcoma: A two-institution study.. Journal of Clinical Oncology, 2013, 31, 10520-10520.	1.6	0
118	Prognostic factors in osteosarcoma: A single institution study.. Journal of Clinical Oncology, 2016, 34, e22503-e22503.	1.6	0
119	A pilot feasibility study of definitive concurrent chemoradiation with pencil beam scanning proton beam in combination with 5-fluorouracil and mitomycin-c for carcinoma of the anal canal.. Journal of Clinical Oncology, 2018, 36, 733-733.	1.6	0
120	Outcomes of intermediate-high grade retroperitoneal sarcomas.. Journal of Clinical Oncology, 2018, 36, e23562-e23562.	1.6	0
121	Updated 5-year local control (LC), metastasis-free survival (MFS), and overall survival (OS) data from a phase I study of nilotinib plus radiation (RT) in high-risk chordoma.. Journal of Clinical Oncology, 2020, 38, e23505-e23505.	1.6	0
122	ASO Visual Abstract:ÂAssessing theÂSafety and UtilityÂof Wound VACÂTemporizationÂof theÂSarcoma or Benign AggressiveÂTumor Bed Until Final Margins are Achieved. Annals of Surgical Oncology, 2022, 29, 2302.	1.5	0